NCT01112358View on ClinicalTrials.gov

Lutropin Alfa in Women at Risk of Poor Response

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 7, 2005

Primary Completion Date

January 30, 2007

Study Completion Date

January 30, 2007

Conditions
Ovarian Stimulation
Interventions
DRUG

r-FSH

r-FSH will be administered as specified in the arm description.

DRUG

r-hLH

r-hLH will be administered as specified in the arm description.

DRUG

Analogous GnRH antagonist

Analogous GnRH antagonist will be administered as specified in the arm description.

DRUG

r-hCG

r-hCG will be administered as specified in the arm description.

DRUG

Progesterone

Progesterone will be administered as specified in the arm description.

Trial Locations (1)

Unknown

Hospital Universitario de La Fe, Valencia

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01112358 - Lutropin Alfa in Women at Risk of Poor Response | Biotech Hunter | Biotech Hunter